<tei>
    <teiHeader>
        <fileDesc xml:id="0"/>
    </teiHeader>
    <text xml:lang="en">
        <listBibl><bibl> <label>[1]</label>C.P. Wild, Environmental exposure measurement in cancer epidemiology, Mutagenesis 24 (2009) 117–125.</bibl>
            <bibl> <label>[2]</label>G.N. Wogan, T.W. Kensler, J.D. Groopman, Present and future directions of translational research on aﬂatoxin and hepatocellular carcinoma. A review, Food Addit. Contam. Part A: Chem. Anal. Control Expos. Risk Assess. 29 (2012) 249–257.</bibl>
            <bibl> <label>[3]</label>H.M. Shen, C.N. Ong, Mutations of the p53 tumor suppressor gene and ras onco- genes in aﬂatoxin hepatocarcinogenesis, Mutat. Res. Rev. Genet. Toxicol. 366 (1996) 23–44.</bibl>
            <bibl> <label>[4]</label>K.A. McGlynn, W.T. London, The global epidemiology of hepatocellular carci- noma: present and future, Clin. Liver Dis. 15 (2011) 223–243.</bibl>
            <bibl> <label>[5]</label>J.F. Solus, B.J. Arietta, J.R. Harris, D.P. Sexton, J.Q. Steward, C. McMunn, P. Ihrie, J.M. Mehall, T.L. Edwards, E.P. Dawson, Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population, Pharmacogenomics 5 (2004) 895–931.</bibl>
            <bibl> <label>[6]</label>C. Ioannides, D.F. Lewis, Cytochromes P450 in the bioactivation of chemicals, Curr. Top. Med. Chem. 4 (2004) 1767–1788.</bibl>
            <bibl> <label>[7]</label>T. Omura, Forty years of cytochrome P450, Biochem. Biophys. Res. Commun. 266 (1999) 690–698.</bibl>
            <bibl> <label>[8]</label>C.N. Martin, R.C. Garner, Aﬂatoxin B1-oxide generated by chemical or enzy- matic oxidation of aﬂatoxin B1 causes guanine substitution in nucleic acids, Nature 267 (1977) 863–865.</bibl>
            <bibl> <label>[9]</label>M.E. Smela, M.L. Hamm, P.T. Henderson, C.M. Harris, T.M. Harris, J.M. Essig- mann, The aﬂatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma, PNAS 99 (2002) 6655–6660.</bibl>
            <bibl> <label>[10]</label>D.W. Nebert, T.P. Dalton, The role of cytochrome P450 enzymes in endoge- nous signalling pathways and environmental carcinogenesis, Nat. Rev. Cancer 6 (2006) 947–960.</bibl>
            <bibl> <label>[11]</label>A. Gunes, M.L. Dahl, Variation in CYP1A2 activity and its clinical implications: inﬂuence of environmental factors and genetic polymorphisms, Pharmacoge- nomics 9 (2008) 625–637.</bibl>
            <bibl> <label>[12]</label>T. Shimada, Xenobiotic-metabolizing enzymes involved in activation and detoxiﬁcation of carcinogenic polycyclic aromatic hydrocarbons, Drug Metab. Pharmacokinet. 21 (2006) 257–276.</bibl>
            <bibl> <label>[13]</label>A.R. Boobis, N.J. Gooderham, K.J. Rich, K. Zhao, R.J. Edwards, B.P. Murray, A.M. Lynch, S. Murray, D.S. Davies, Enzymatic studies of the activation of heterocyclic food mutagens in man, Princess Takamatsu Symp. 23 (1995) 134–144.</bibl>
        </listBibl>
    </text>
</tei>
